Theranexus Société Anonyme (ALTHX.PA)
EUR 0.64
(32.37%)
EUR 0.64
(32.37%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 2.46 Million EUR | -31.74% |
| 2022 | 3.6 Million EUR | -32.32% |
| 2021 | 5.32 Million EUR | -6.63% |
| 2020 | 5.7 Million EUR | 173.55% |
| 2019 | 2.08 Million EUR | -24.92% |
| 2018 | 2.77 Million EUR | 493.36% |
| 2017 | 468.16 Thousand EUR | -73.32% |
| 2016 | 1.75 Million EUR | 250.64% |
| 2015 | 500.46 Thousand EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 1.75 Million EUR | 0.0% |
| 2023 Q2 | 2.89 Million EUR | 0.0% |
| 2023 Q4 | 2.46 Million EUR | 0.0% |
| 2023 FY | 2.46 Million EUR | -31.74% |
| 2022 Q2 | 4.67 Million EUR | 0.0% |
| 2022 FY | 3.6 Million EUR | -32.32% |
| 2022 Q4 | 3.6 Million EUR | 0.0% |
| 2021 Q2 | 4.57 Million EUR | 0.0% |
| 2021 FY | 5.32 Million EUR | -6.63% |
| 2021 Q4 | 4.18 Million EUR | 0.0% |
| 2020 Q2 | 3.47 Million EUR | 0.0% |
| 2020 Q4 | 5.7 Million EUR | 0.0% |
| 2020 FY | 5.7 Million EUR | 173.55% |
| 2019 FY | 2.08 Million EUR | -24.92% |
| 2019 Q4 | 2.08 Million EUR | 0.0% |
| 2019 Q2 | 2.43 Million EUR | 0.0% |
| 2018 Q2 | 315 Thousand EUR | 0.0% |
| 2018 Q4 | 2.77 Million EUR | 0.0% |
| 2018 FY | 2.77 Million EUR | 493.36% |
| 2017 Q2 | 1.79 Million EUR | 0.0% |
| 2017 FY | 468.16 Thousand EUR | -73.32% |
| 2017 Q4 | 468.16 Thousand EUR | 0.0% |
| 2016 Q4 | 1.75 Million EUR | 0.0% |
| 2016 FY | 1.75 Million EUR | 250.64% |
| 2015 FY | 500.46 Thousand EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -123.498% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 94.495% |
| Adocia SA | 4.54 Million EUR | 45.799% |
| Aelis Farma SA | 2.04 Million EUR | -20.152% |
| Biophytis S.A. | 3.11 Million EUR | 20.903% |
| Advicenne S.A. | 15.89 Million EUR | 84.52% |
| genOway Société anonyme | 5.51 Million EUR | 55.416% |
| IntegraGen SA | 642.28 Thousand EUR | -283.122% |
| Medesis Pharma S.A. | 1.2 Million EUR | -105.06% |
| Neovacs S.A. | 650 Thousand EUR | -278.572% |
| NFL Biosciences SA | 39.2 Thousand EUR | -6176.861% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 43.516% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | -25.526% |
| Sensorion SA | 1.24 Million EUR | -98.299% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | 36.872% |
| TheraVet SA | 1 Million EUR | -145.924% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | 64.368% |
| argenx SE | 15.35 Million EUR | 83.973% |
| BioSenic S.A. | 15.57 Million EUR | 84.199% |
| Celyad Oncology SA | 902 Thousand EUR | -172.807% |
| DBV Technologies S.A. | 4.52 Million USD | 45.632% |
| Galapagos NV | 4.94 Million EUR | 50.228% |
| Genfit S.A. | 62.25 Million EUR | 96.047% |
| GeNeuro SA | 6.49 Million EUR | 62.098% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -615.325% |
| Innate Pharma S.A. | 30.6 Million EUR | 91.96% |
| Inventiva S.A. | 25.61 Million EUR | 90.394% |
| MaaT Pharma SA | 5.42 Million EUR | 54.641% |
| MedinCell S.A. | 52.8 Million EUR | 95.34% |
| Nanobiotix S.A. | 41.66 Million EUR | 94.093% |
| Onward Medical N.V. | 16.3 Million EUR | 84.909% |
| Oryzon Genomics S.A. | 3.45 Million EUR | 28.688% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | 93.07% |
| Oxurion NV | 117 Thousand EUR | -2003.178% |
| Pharming Group N.V. | 123.65 Million EUR | 98.01% |
| Poxel S.A. | 40.14 Million EUR | 93.87% |
| GenSight Biologics S.A. | 1.04 Million EUR | -134.801% |
| Transgene SA | 17 Thousand EUR | -14374.812% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 99.914% |
| Valneva SE | 132.76 Million EUR | 98.147% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |